To further explore the clinical significance of CD63+ CAFs in breast cancer, we generated a gene signature to evaluate the abundance of CD63+ CAFs in primary breast tumors and performed an analysis with the TCGA dataset. This evidence concerns the gene CD63 and breast neoplasm.